Linagliptin

Name: Linagliptin
SKU: L337521
Availability: InStock

Product ID L337521

Cas No. 668270-12-0

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

Linagliptin is a dipeptidyl peptidase 4 inhibitor glucose-lowering compound with low risk of inducing hypoglycaemia. It has been found that linagliptin may modify several measures of microvascular function including hyperaemia area, resting blood flow, and peak blood flow in the fasting state. Treatment of STZ-diabetic Wistar rats was shown to decreases levels of oxidative stress, protect against microvascular damage, enhance neuronal cell survival, and prevent vasoregression.
Furthermore, treatment was found to decrease aortic pulse wave velocity, glycated haemoglobin, fasting plasma glucose, and triglycerides in people with early type 2 diabetes. Contrarily, linagliptin has also been known to cause adverse reactions such as ulcers and blisters.

Product Info

Cas No.	668270-12-0
Purity	≥98%
Formula	C₂₅H₂₈N₈O₂
Formula Wt.	472.55
Chemical Name	8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
IUPAC Name	8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Synonym	Tradjenta, BI 1356, Ondero
Solubility	Soluble in DMSO (17 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (1 mg/ml at 25 °C), 0.5% hyroxyethylcellulose (30 mg/ml at 25 °C), and methanol.

Shipping and Storage

Store Temp	-20°C
Ship Temp	Ambient

Downloads

MSDS	L337521 MSDS PDF
Info Sheet	L337521 Info Sheet PDF

References

Jax T, Stirban A, Terjung A, et al. A randomized, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. PMID: 28109295.

Dietrich N, Kolibabka M, Busch S, et al. The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy. PLoS One. 2016 Dec 12;11(12):e0167853. PMID: 27942008.

de Boer SA, Heerspink HJL, Juarez Orozco LE, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab. 2017 Aug;19(8):1147-1154. PMID: 28244635.

Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. BMJ Case Rep. 2017 May 31;2017. PMID: 28566414.

Custom Order

Name*
First Last
Company/Institution
Email*
Enter Email Confirm Email
Product ID
Product Name
Unit Size
Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
Unit Label
Quantity
Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
Comments
Phone
This field is for validation purposes and should be left unchanged.

Linagliptin

Quicklinks

Description

Product Info

Shipping and Storage

Downloads

References

Custom Order

Related Products

Ramoplanin

Hypaconitine

S-Nitrosoglutathione

Lumiracoxib

Acetylsalicylic Acid

Dexrazoxane

Inositol

Sucralfate

Plasminogen Activator Inhibitor 1

Nivalenol

Epoxiconazole

Dihydrocytochalasin B

Saikosaponin D

Walrycin B

S-Trityl-L-cysteine

Catharanthine Sulfate

MSA-2

RKI-1447

Paclitaxel, 8-Hydro-bicyclo(3.3.0)octane

Diclofenac Chloroacetyl impurity

Footer